Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma.

Evaluation of Daratumumab Drug Effect in Immunoglobulin (Ig) G and Non-IgG Myeloma Patients The effect of daratumumab was highly significant in the overall population of patients receiving 16 mg/kg ( p < 0.0001), as well as in patients with IgG ( p < 0.0001) and non-IgG MM ( p = 0.004) [Table 2 ].

also in 132,142 other papers

Our previous research demonstrated that there was a weak trend toward higher rates of infection of any grade with greater daratumumab exposure, but this observation did not reach statistical significance and a similar trend was not observed for grade 3 or higher infections.

also in 1,404 other papers